How Quickly Does Zavzpret Relieve Acute Migraine Pain?
Zavzpret (zavegepant) nasal spray starts working fast for acute migraine treatment. In clinical trials, it reduced pain significantly within 15 minutes, with 25-30% of patients pain-free by 30 minutes after a single dose. By 2 hours, about 40% achieved pain freedom, outperforming placebo (around 15%). These results come from phase 3 studies involving over 1,800 adults with moderate to severe migraines.[1][2]
What About Other Migraine Symptoms Like Nausea or Light Sensitivity?
Zavzpret also tackles most bothersome symptoms quickly. In trials, relief from nausea, vomiting, photophobia, and phonophobia hit at similar speeds: significant improvement by 15 minutes and sustained through 2 hours. Around 35-40% of patients were free of these symptoms by 2 hours, compared to 12-20% on placebo.[1][3]
How Does Its Speed Stack Up Against Other Migraine Nasal Sprays?
Zavzpret acts faster than some options like sumatriptan nasal spray (which peaks at 1-2 hours for pain relief). It matches or beats gepants like ubrogepant (oral, 2-hour onset) since nasal delivery bypasses the gut for quicker absorption during nausea. Unlike injectables like sumatriptan auto-injector (10-15 minutes), it's noninvasive.[2][4]
Factors That Affect How Fast It Works for You
Onset can vary by migraine severity, prior treatments, and individual factors like nasal congestion. Trials excluded patients with substantial congestion; real-world use might slow absorption slightly. Dosing is one spray (10 mg) per nostril; a second dose isn't recommended within 24 hours.[1][5]
When Does Full Pain Relief Kick In, and How Long Does It Last?
Peak effects occur by 1 hour, with pain relief lasting up to 48 hours for many. If no improvement by 2 hours, guidelines suggest trying another acute treatment, as consistent responders see benefits early.[2][3]
Sources:
[1] Zavzpret.com (prescribing information and trial data)
[2] New England Journal of Medicine: Phase 3 trial results
[3] Pfizer press release on ZAVZPRET trials
[4] Migraine Disorders Association comparison
[5] FDA prescribing label